China has approved 59 innovative drugs year-to-date, including 13 with novel mechanisms or targets, signaling steady gains in original innovation capacity. From January–August there were 113 biopharma business-development deals nationwide totaling $119.997 billion; Shanghai led with 37 deals, or 33% of the national total. Shanghai’s biopharma sector reached 500.566 billion yuan in 1H2025 and is forecast to exceed 1 trillion yuan in 2026, becoming the city’s fifth trillion-yuan industry cluster.

2026-09-17

China has approved 59 innovative drugs year-to-date, including 13 with novel mechanisms or targets, signaling steady gains in original innovation capacity. From January–August there were 113 biopharma business-development deals nationwide totaling $119.997 billion; Shanghai led with 37 deals, or 33% of the national total. Shanghai’s biopharma sector reached 500.566 billion yuan in 1H2025 and is forecast to exceed 1 trillion yuan in 2026, becoming the city’s fifth trillion-yuan industry cluster.